Opinion|Videos|February 25, 2025
Patient Voices: Shaping the Future of PNH Care
Author(s)David Dingli, MD, PhD, Brandi Lewis
Panelists discuss how their lived experiences and insights as patients should inform research priorities, treatment development, and care delivery improvements while sharing hopes for a future cure that would eliminate ongoing disease management needs and allow greater life flexibility.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What role do you think patient voices should play in guiding future advancements in paroxysmal nocturnal hemoglobinuria (PNH) care?
- How do you imagine your life might change if there were a cure for PNH in the future?
This program was made possible with support from Novartis Pharmaceuticals.
Advertisement
Related to this article
The FDA granted platform technology designation to the immunotherapeutic platform for use in HPV-positive cancers such as head and neck, cervical, and anal.
An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.
Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.
The updated NCCN Guidelines for myeloproliferative neoplasms recommend rusfertide as a category 1 option across both low- and high-risk polycythemia vera.
As part of the ANDA pathway, Bravnetsa is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product, Lutathera.
Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.
Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
2
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
3
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
4
COA Warns That Price Negotiation for Medicare Part B Drugs Threatens Community Oncology
5